Adverse Effects of Low‐Dose Methotrexate in a Randomized Double‐Blind Placebo‐Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial is a research paper published in ACR Open Rheumatology (2020). On theSindex it has a DataRank of 0.515. It has been cited 30 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.515
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: NIH R01 HL119718
National Institutes of Health
Grant: NIH U01 HL101389
National Institutes of Health
Grant: NIH U01 HL101422
NHLBI NIH HHS
Grant: U01 HL101389
NHLBI NIH HHS
Grant: U01 HL101422
NHLBI NIH HHS
Grant: R01 HL119718
National Institutes of Health
Grant: 5R01HL119718-04
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study
National Institutes of Health
Grant: 1U01HL101422-01A1
Cardiovascular Inflammation Reduction Trial (CIRT)
National Institutes of Health
Grant: 5U01HL101389-05
Cardiovascular Inflammation Reduction Trial (CIRT): DCC
FWCI
2.70
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals